Shown are the clinical characteristics of the 31 IBD patients who underwent solid organ transplantation (SOT).

Disease classification was performed as detailed in the Materials and Methods section (n. a., not applicable; DALM, dysplasia-associated lesion or mass; 5-ASA, 5-aminosalicylic acid; AZA, azathioprine; 6-MP, 6-mercaptopurine; ADA, adalimumab; IFX, infliximab; LTx, liver transplantation; Tx, transplantation; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; DALM, Dysplasia-associated lesion or mass; HCC, hepatocellular carcinoma; CCC, cholangio-cellular carcinoma; CRF, chronic renal failure; MMF, mycophenolate mofetil; CyA, cyclosporine A; tac, tacrolimus).
Given are sex, age, anti-reject immunosuppressive regimen, malignancies before/after organ transplantation, re-transplantation and reason for re-transplantation and severe complications after SOT, IBD activity before and after SOT, medical treatment of IBD and history of CD-related surgeries. The diagnosis and classification of UC and CD was based on the Montreal classification including endoscopic, radiological, and histopathological parameters [43].